Remove 2019 Remove Communication Remove Documentation
article thumbnail

White paper reveals pathway for digital therapeutics use in Italy

pharmaphorum

The experts were also involved in the “Digital Therapeutics for Italy – #DTxITA”, established in 2019 to encourage the implementation of DTx in Italian institutions and healthcare systems. Healthware Group, an international integrated consulting group also based in Italy, contributed to the white paper.

article thumbnail

Teva faces EU antitrust probe over MS drug Copaxone

pharmaphorum

The Commission will also examine whether Teva may have launched a communication campaign to create a “false perception” about the health risks of prescribing generic competitors, aimed at healthcare professionals and hospitals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New regulatory relief to benefit Europe’s pharma SMEs

European Pharmaceutical Review

As small and medium-sized enterprises (SMEs) often face unfair competition when doing business in Europe, through the (SME) Relief Communication, the European Commission (EC) has proposed new measures to provide short-term relief, boost long-term competitiveness, and improve equality in the business environment across the Single Market in Europe.

article thumbnail

Time to change the channel? The future for customer engagement models

pharmaphorum

While remote communication with HCPs rose in all countries in the same time period, not all remote engagement was the type likely to be described as meaningful – much of the volume was in emails, with WhatsApp, and other remote messaging, also important during the peak infection period. In the US, the trend had already started pre-COVID-19.

article thumbnail

Building an integrated vector supply to support autologous cell therapy for solid tumours

European Pharmaceutical Review

An analysis performed at the end of 2019 concluded that demand for viral vectors would have surpassed CDMO capacity during 2020. Another factor in this enhanced adaptability is development of in-house expertise that enables more efficient interaction by simplifying communication channels.

Vaccines 115
article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

In 2020, the FDA released a guidance document for the industry with recommendations for sponsors developing gene therapies for rare diseases. This document delved into aspects related to manufacturing, preclinical, and clinical trial design for all phases of clinical development.

FDA 105
article thumbnail

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part iii)

pharmaphorum

A Member of the European Parliament since 2019, she stated that what happens in a crisis is that existing inequalities get exaggerated. There were communication and psychology problems, he explained, and documentation was scarce or missing. Fitzgerald opened the discussion.